News - Watson Pharmaceuticals, Pharmaceutical

Filter

Popular Filters

1 to 25 of 27 results

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

AstraZeneca in Crestor patent settlement with Actavis and EGIS Pharma

25-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a settlement agreement in its US patent…

ActavisCardio-vascularCrestorGenericsNorth AmericaPatentsPharmaceuticalrosuvastatinShionogiWatson Pharmaceuticals

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015

06-03-2013

Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Pfizer prevails in Rapamune patent dispute with Watson

01-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) says that the US District Court for the District of Delaware…

ActavisGenericsImmunologicalsLegalNorth AmericaPatentsPfizerPharmaceuticalRapamuneWatson Pharmaceuticals

Watson acquires Uteron Pharma; confirms Opana patent challenge

24-01-2013

US generic and specialty drugmaker Watson Pharmaceuticals (NYSE: WPI) says that it has completed the…

Endo PharmaceuticalsGenericsGrunenthalMergers & AcquisitionsNeurologicalNorth AmericaOpanaPatentsPharmaceuticalUteron PharmaWatson PharmaceuticalsWomen's Health

Patent cliff: one drugmaker's sorrow is another one's joy

20-01-2013

The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers…

DilantinGenericsLystedaMarkets & MarketingMylan LaboratoriesNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

US Supreme Court agrees to review pay-for-delay generic deals

10-12-2012

The US Supreme Court has agreed to a request by the Federal Trade Commission to look into the practice…

GenericsLegalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Forest Labs links with moksha8 for Viibryd in Latin America; Watson sells minority stake

24-10-2012

US drugmaker Forest Laboratories (NYSE: FRX) has entered into a broad strategic alliance with Brazil-based…

Forest LaboratoriesGenericsLicensingMergers & AcquisitionsMoksha8NeurologicalPharmaceuticalSouth AmericaViibrydWatson Pharmaceuticals

FTC seeks US Supreme Court review in AndroGel "pay-for-delay" case

08-10-2012

At the request of the US Federal Trade Commission, the Solicitor General of the USA petitioned the country's…

Abbott LaboratoriesAndroGelGenericsLegalMen's HealthNorth AmericaPatentsPharmaceuticalSolvayWatson Pharmaceuticals

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

FDA delays approval of QRxPharma's pain drug MoxDuo

29-06-2012

The US Food and Drug Administration has issued a Complete Response Letter (CRL) regarding the New Drug…

ActavisMoxDuoNeurologicalNorth AmericaPharmaceuticalQRxPharmaRegulationWatson Pharmaceuticals

Watson challenges Pfizer's Pristiq patent

26-06-2012

US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

GenericsNeurologicalNorth AmericaPatentsPfizerPharmaceuticalPristiqRegulationWatson Pharmaceuticals

Shire to face generic competition for Adderall XR from Actavis

25-06-2012

Shares in UK drugmaker Shire (LSE: SHP) fell around 9% to £17.82 in early trading this morning,…

ActavisAdderall XRGenericsNeurologicalNorth AmericaPharmaceuticalRegulationShireWatson Pharmaceuticals

News briefs from Sanofi, EpiCept/Meda, Horizon/Grunenthal and Watson

20-06-2012

French drug major Sanofi (Euronext: SAN) and the Joslin Diabetes Center, a teaching and research affiliate…

AllerganAnti-Arthritics/RheumaticsCepleneDiabetesDuexisEpiCeptGenericsGenito-urinaryGrunenthalHorizon PharmaLicensingMedaOncologyPatentsPharmaceuticalResearchSanctura XRSanofiWatson Pharmaceuticals

Depomed to file NDA for Serada; with Valeant sues Watson over Glumetza

20-04-2012

US drugmaker Depomed (Nasdaq: DEPO) says that it has completed a Type B pre-New Drug Application meeting…

DepomedDiabetesGenericsGlumetzaNorth AmericaPatentsPharmaceuticalRegulationResearchSeradaValeant PharmaceuticalsWatson PharmaceuticalsWomen's Health

ViroPharma stock plunges on bad news for Vancocin; Sanofi patents invalidated

11-04-2012

ViroPharma I (Nasdaq: VPHM) saw its shares plunge 19% to $23.25 yesterday after it announced that the…

Antibiotics and Infectious diseasesApotexGenericsHospiraLegalNorth AmericaOncologyPatentsPharmaceuticalRegulationSanofiTaxotereVancocinViroPharmaWatson Pharmaceuticals

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis

29-03-2012

There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Depomed files patent infringement suits relating to Gralise

05-03-2012

California, USA-based Depomed (Nasdaq: DEPO) yesterday filed a patent infringement law suit in the US…

ActavisDepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Columbia Labs hands over NDA to Watson

13-02-2012

Columbia Laboratories (Nasdaq: CBRX) has transferred the New Drug Application for progesterone vaginal…

Columbia LaboratoriesCrinoneLicensingNorth AmericaPharmaceuticalRegulationReproductiveWatson PharmaceuticalsWomen's Health

FDA Advisory thumbs down for Columbia and Watson product

23-01-2012

US drugmakers Columbia Laboratories (Nasdaq: CBRX) and Watson Pharmaceuticals (NYSE: WPI) confirmed on…

Columbia LaboratoriesCrinoneNorth AmericaPharmaceuticalRegulationReproductiveWatson PharmaceuticalsWomen's Health

Overactive bladder gel gets FDA nod

09-12-2011

The US Food and Drug Administration (FDA) has approved US drugmaker Antares Pharma’s (NYSE Amex:…

Antares PharmaGenito-urinaryNorth AmericaOxybutyninPharmaceuticalRegulationWatson Pharmaceuticals

Watson and Ranbaxy kick off genericization of Lipitor, launching their approved copies in USA

01-12-2011

US generic drug major Watson Pharmaceuticals (NYSE: WPI) was the first to confirm yesterday that it has…

atorvastatinCardio-vascularGenericsLipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRanbaxy LaboratoriesTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Growing scrutiny of pharma facilities exacerbating US drug shortage situation, claims Watson CEO

29-09-2011

Intensifying regulatory inspections of pharmaceutical manufacturing facilities are causing record shortages…

GenericsMarkets & MarketingNorth AmericaPharmaceuticalRegulationWatson Pharmaceuticals

1 to 25 of 27 results

Back to top